<SEC-DOCUMENT>0001571049-17-006523.txt : 20170706
<SEC-HEADER>0001571049-17-006523.hdr.sgml : 20170706
<ACCEPTANCE-DATETIME>20170706170159
ACCESSION NUMBER:		0001571049-17-006523
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20170706
DATE AS OF CHANGE:		20170706

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-218305
		FILM NUMBER:		17952733

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>t1702049_s1a.htm
<DESCRIPTION>AMENDMENT NO. 2 TO FORM S-1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>As filed with
the Securities and Exchange Commission on July 6 , 2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>Registration No. 333-218305</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES&nbsp;<BR>
SECURITIES AND EXCHANGE COMMISSION&nbsp;<BR>
Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Amendment No.
2 to&nbsp;</B><BR>
<B>FORM S-1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>REGISTRATION STATEMENT&nbsp;<BR>
UNDER THE SECURITIES ACT OF 1933</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 14pt"><B>CYCLACEL
PHARMACEUTICALS, INC.</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 12pt"><B></B></FONT><FONT STYLE="font-size: 8pt">(Exact name of registrant as specified in its charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%; text-align: center; font-size: 11pt; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 50%; text-align: center; font-size: 11pt; padding-right: 0; padding-left: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>91-1707622</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; font-size: 11pt; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(State or other jurisdiction of</FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">incorporation or organization)</FONT></TD>
    <TD STYLE="text-align: center; font-size: 11pt; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">IRS Employer</FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Identification Number)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>200 Connell
Drive, Suite 1500&nbsp;</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Berkeley Heights, NJ 07922&nbsp;</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>(908) 517-7330&nbsp;</B></FONT><BR>
<FONT STYLE="font-size: 8pt">(Address, including zip code, and telephone number, including area code, of registrant&rsquo;s principal
executive offices)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Spiro Rombotis&nbsp;</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Chief Executive Officer&nbsp;</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Cyclacel Pharmaceuticals, Inc.&nbsp;</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>200 Connell Drive, Suite 1500&nbsp;</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Berkeley Heights, NJ 07922&nbsp;</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>(908) 517-7330&nbsp;</B></FONT><BR>
<FONT STYLE="font-size: 8pt">(Name, address, including zip code, and telephone number, including area code, of agent for service)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>With copies to:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: center; font-size: 11pt; padding-right: 0; padding-left: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Joel I. Papernik, Esq.</B></FONT><BR>
<FONT STYLE="font: 10pt Times New Roman, Times, Serif">Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.&nbsp;</FONT><BR>
<FONT STYLE="font: 10pt Times New Roman, Times, Serif">666 Third Avenue&nbsp;</FONT><BR>
<FONT STYLE="font: 10pt Times New Roman, Times, Serif">New York, New York 10017&nbsp;</FONT><BR>
<FONT STYLE="font: 10pt Times New Roman, Times, Serif">(212) 935-3000</FONT></TD>
    <TD STYLE="width: 50%; text-align: center; font-size: 11pt; padding-right: 0; padding-left: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Michael Nertney</B></FONT><BR>
<FONT STYLE="font: 10pt Times New Roman, Times, Serif">Ellenoff Grossman &amp; Schole LLP&nbsp;</FONT><BR>
<FONT STYLE="font: 10pt Times New Roman, Times, Serif">1345 Avenue of the Americas&nbsp;</FONT><BR>
<FONT STYLE="font: 10pt Times New Roman, Times, Serif">New York, New York 10105&nbsp;</FONT><BR>
<FONT STYLE="font: 10pt Times New Roman, Times, Serif">(212) 370-1300</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Approximate date of commencement of proposed
sale to public: as soon as practicable after this registration statement becomes effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under
the Securities Act of 1933, check the following box:&ensp;</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check
the following box and list the Securities Act registration statement number of the earlier effective registration statement for
the same offering:&ensp;</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier effective registration statement for the same offering:&ensp;</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become
effective upon filing with the Commission pursuant to Rule 462(d) under the Securities Act, check the following box:&ensp;</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions
of&thinsp; &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; and &ldquo;smaller reporting company&rdquo;
in Rule 12b-2 of the Exchange Act. (Check one):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 3.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer&ensp;</FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer&ensp;</FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer&ensp;</FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company&ensp;</FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt">x</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Do not check if a smaller reporting company)</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter). </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT>
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <B>EXPLANATORY
NOTE</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> This Amendment No. 2 (this &quot;Amendment&quot;)
relates to the Registrant's Registration Statement on Form S-1 (File No. 333-218305), which was initially filed with the Securities
and Exchange Commission on May 26, 2017, as amended on June 30, 2017. The Registrant is filing this Amendment for the sole purpose
of replacing Exhibit 5.1 to the Registration Statement. This Amendment does not modify any provision of Part I or Part II of the
Registration Statement other than Item 16 of Part II as set forth below. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PART II &mdash; INFORMATION NOT REQUIRED
IN PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 13.&nbsp;&nbsp;&nbsp;Other Expenses of Issuance and
Distributions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%; text-align: left">Securities and Exchange Commission Registration Fee*</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">3,098.88</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Legal Fees and Expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">175,000.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accounting Fees and Expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,000.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Miscellaneous Expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,000.00</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">199,098.88</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">*All expenses except the registration fee are estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 14.&nbsp;&nbsp;&nbsp;Indemnification of Directors and
Officers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Our amended and restated certificate of incorporation,
as amended, and amended and restated bylaws, as amended, provide that each person who was or is made a party or is threatened to
be made a party to or is otherwise involved (including, without limitation, as a witness) in any action, suit or proceeding, whether
civil, criminal, administrative or investigative, by reason of the fact that he or she is or was a director or an officer of Cyclacel
Pharmaceuticals, Inc. or is or was serving at our request as a director, officer, or trustee of another corporation, or of a partnership,
joint venture, trust or other enterprise, including service with respect to an employee benefit plan, whether the basis of such
proceeding is alleged action in an official capacity as a director, officer or trustee or in any other capacity while serving as
a director, officer or trustee, shall be indemnified and held harmless by us to the fullest extent authorized by the Delaware General
Corporation Law against all expense, liability and loss (including attorneys&rsquo; fees, judgments, fines, ERISA excise taxes
or penalties and amounts paid in settlement) reasonably incurred or suffered by such.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Section 145 of the Delaware General Corporation
Law permits a corporation to indemnify any director or officer of the corporation against expenses (including attorney&rsquo;s
fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with any action, suit or
proceeding brought by reason of the fact that such person is or was a director or officer of the corporation, if such person acted
in good faith and in a manner that he reasonably believed to be in, or not opposed to, the best interests of the corporation, and,
with respect to any criminal action or proceeding, if he or she had no reason to believe his or her conduct was unlawful. In a
derivative action, (i.e., one brought by or on behalf of the corporation), indemnification may be provided only for expenses actually
and reasonably incurred by any director or officer in connection with the defense or settlement of such an action or suit if such
person acted in good faith and in a manner that he or she reasonably believed to be in, or not opposed to, the best interests of
the corporation, except that no indemnification shall be provided if such person shall have been adjudged to be liable to the corporation,
unless and only to the extent that the court in which the action or suit was brought shall determine that the defendant is fairly
and reasonably entitled to indemnity for such expenses despite such adjudication of liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Pursuant to Section 102(b)(7) of the Delaware
General Corporation Law, our amended and restated certificate of incorporation eliminates the liability of a director to us or
our stockholders for monetary damages for such a breach of fiduciary duty as a director, except for liabilities arising:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 38pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">from any breach of the director&rsquo;s duty of loyalty to us or our
stockholders;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 38pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">from acts or omissions not in good faith or which involve intentional
misconduct or a knowing violation of law;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56pt; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Symbol; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 38pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">under Section 174 of the Delaware General Corporation Law; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 38pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">from any transaction from which the director derived an improper personal
benefit.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">We carry insurance policies insuring our
directors and officers against certain liabilities that they may incur in their capacity as directors and officers. In addition,
we expect to enter into indemnification agreements with each of our directors and executive officers prior to completion of the
offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">The Company has entered into indemnification
agreements with each of its directors and executive officers. Pursuant to the indemnification agreements, the Company agrees to
hold harmless and indemnify its directors and executive officers to the fullest extent authorized or permitted by the provisions
of the Company&rsquo;s amended and restated certificate of incorporation, amended and restated by-laws and the DGCL, including
for any amounts that such director or officer becomes obligated to pay because of any claim to which such director or officer is
made or threatened to be made a party, witness or participant, by reason of such director&rsquo;s or officer&rsquo;s service as
a director, officer, employee or other agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">There are certain exceptions from the Company&rsquo;s
obligation to indemnify its directors and executive officers pursuant to the indemnification agreements, including for &ldquo;short-swing&rdquo;
profit claims under Section 16(b) of the Securities Exchange Act of 1934, as amended, losses that are as a result of conduct that
is established by a final judgment as knowingly fraudulent or deliberately dishonest or that constituted willful misconduct, or
that constituted a breach of the duty of loyalty to the Company or resulted in any improper personal profit or advantage, where
payment is actually made to a director or officer under an insurance policy, indemnity clause, bylaw or agreement, except in respect
of any excess beyond payment under such insurance, clause, bylaw or agreement, for indemnification which is not lawful, or in connection
with any proceeding initiated by such director or officer, or any proceeding against the Company or its directors, officers, employees
or other agents, unless (i) such indemnification is expressly required to be made by law, (ii) the proceeding was authorized by
the board of directors of the Company, (iii) such indemnification is provided by the Company, in its sole discretion, pursuant
to the powers vested in the Company under the DGCL, or (iv) the proceeding is initiated to enforce a claim for indemnification
pursuant to the indemnification agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">All agreements and obligations of the Company
contained in the indemnification agreements shall continue during the period when the director or officer who is a party to an
indemnification agreement is a director, officer, employee or other agent of the Company (or is or is serving at the request of
the Company as a director, officer, employee or other agent of another corporation, partnership, joint venture, trust, employee
benefit plan or other enterprise) and shall continue thereafter so long as such director or officer shall be subject to any possible
claim or threatened, pending or completed action, suit or proceeding, whether civil, criminal, arbitrational, administrative or
investigative. In addition, the indemnification agreements provide for partial indemnification and advance of expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Insofar as indemnification for liabilities
arising under the Securities Act of 1933, as amended, may be permitted to our directors, officers or controlling persons pursuant
to the foregoing provisions, or otherwise, we have been advised that in the opinion of the Securities and Exchange Commission this
indemnification is against public policy as expressed in the Securities Act of 1933, as amended, and is, therefore, unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 15.&nbsp;&nbsp;&nbsp;Recent Sales of Unregistered Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">In the three years preceding the filing of
this Registration Statement, we have sold the following securities that were not registered under the Securities Act. The following
information gives effect to a one-for-twelve reverse stock split of our common stock effected on May&nbsp;31, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>FBR Sales Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">On June&nbsp;23, 2016, the Company entered
into a sales agreement with FBR (the &ldquo;FBR Sales Agreement&rdquo;), under which the Company may issue and sell shares of its
common stock, from time to time through FBR, acting as its</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">sales agent. Under the FBR Sales Agreement, FBR may sell the
shares of common stock by any method that is deemed to be an &ldquo;at the market offering&rdquo;. The Company will pay FBR a commission
of 3.0% of the gross sales price per share sold. The Company is not obligated to make any sales of common stock under the FBR Sales
Agreement. In the three months ended March&nbsp;31, 2017, the Company sold 16,118 shares of common stock under the sales agreement
for net proceeds of approximately $0.1 million. During April&nbsp;2017, the Company sold a further 167,000 shares of common stock
for net proceeds of approximately $1.0 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Aspire Stock Purchase Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">On November&nbsp;14, 2013, the Company
entered into a common stock purchase agreement with Aspire (the &ldquo;Aspire Purchase Agreement&rdquo;). Upon execution of
the Aspire Purchase Agreement, Aspire purchased 42,626 shares of common stock for an aggregate purchase price of&thinsp; $2.0
million. During the year ended December&nbsp;31, 2015, the Company sold all remaining 117,869 shares of common stock that
were subject to the Aspire Purchase Agreement for net proceeds of approximately $1.4 million and the Aspire Purchase
Agreement was automatically terminated by its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 16.&nbsp;&nbsp;&nbsp;Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 11%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Exhibit</B></FONT><B><FONT STYLE="font-size: 8pt"><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif">Number</FONT></FONT></B></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="width: 88%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1**</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Underwriting Agreement.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Certificate of Incorporation of Cyclacel Pharmaceuticals, Inc. (previously filed as Exhibit 3.1 to the Registrant&rsquo;s Annual Report on Form 10-K, originally filed with the SEC on April&nbsp;1, 2013, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Cyclacel Pharmaceuticals, Inc. (previously filed as Exhibit 3.1 to the Registrant&rsquo;s Current Report on Form 8-K, originally filed with the SEC on May&nbsp;27, 2016, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Bylaws of Cyclacel Pharmaceuticals, Inc. (Previously filed as Exhibit 3.2 to the Registrant&rsquo;s Annual Report on Form 10-K, File No. 000-50626, originally filed with the SEC on March&nbsp;31, 2011 and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Designation of 6% Convertible Exchangeable Preferred Stock (previously filed as Exhibit 3.2 to the Registrant&rsquo;s Current Report on Form 8-K, originally filed with the SEC on November&nbsp;5, 2004, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5**</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Designation of Series A Preferred Stock.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Common Stock Certificate (previously filed as Exhibit 4.1 to Registrant&rsquo;s Registration Statement on Form S-1, File No. 333-109653, originally filed with the SEC on October&nbsp;10, 2003, as subsequently amended, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2**</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Series A Preferred Stock Certificate.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3**</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant to purchase shares of Cyclacel Pharmaceuticals, Inc. Common Stock to be issued in the Offering.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock Purchase Agreement, dated December&nbsp;15, 2005, between Xcyte Therapies, Inc., and Cyclacel Group plc (previously filed as Exhibit 2.1 to the Registrant&rsquo;s Current Report on Form 8-K, originally filed with the SEC on December&nbsp;20, 2005, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No. 1 to the Stock Purchase Agreement, dated January&nbsp;13, 2006, between Xcyte Therapies Inc., and Cyclacel Group plc (previously filed as Exhibit 2.1 to the Registrant&rsquo;s current report on Form 8-K filed with the Commission on January&nbsp;19, 2006, and incorporated herein by reference).</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 11%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Exhibit</B></FONT><B><FONT STYLE="font-size: 8pt"><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif">Number</FONT></FONT></B></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="width: 88%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3&dagger;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Equity Incentive Plan (previously filed as Exhibit 10.1 to Registrant&rsquo;s Current Report on Form 8-K, originally filed with the SEC on May&nbsp;24, 2012, and incorporated by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4&dagger;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity Incentive Plan (previously filed as Exhibit 10.1 to Registrant&rsquo;s Current Report on Form 8-K, originally filed with the SEC on May&nbsp;22, 2015, and incorporated by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5&dagger;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement by and between Cyclacel Pharmaceuticals, Inc. and Spiro Rombotis, dated as of January&nbsp;1, 2014 (previously filed as Exhibit 10.4 to the Registrant&rsquo;s Annual Report on Form 10-K, originally filed with the SEC on March&nbsp;24, 2014, and incorporated by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6&dagger;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement by and between Cyclacel Pharmaceuticals, Inc. and Paul McBarron, dated as of January&nbsp;1, 2014 (previously filed as Exhibit 10.5 to the Registrant&rsquo;s Annual Report on Form 10-K, originally filed with the SEC on March&nbsp;24, 2014, and incorporated by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7&dagger;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Change in Control Agreement by and between Cyclacel Pharmaceuticals, Inc. and Dr.&nbsp;Judy Chiao, dated as of December&nbsp;10, 2010 (previously filed as Exhibit 10.1 to the Registrant&rsquo;s Current Report on Form 8-K, originally filed with the SEC on December&nbsp;14, 2010, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement between the Company and Scottish Enterprise dated March&nbsp;27, 2006 (previously filed as Exhibit 10.2 to the Registrant&rsquo;s Quarterly Report on Form 10-Q, for the quarterly period ended June&nbsp;30, 2009, originally filed with the SEC on August&nbsp;13, 2009, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Addendum to Agreement between the Company and Scottish Enterprise dated June&nbsp;22, 2009 (previously filed as Exhibit 10.3 to the Registrant&rsquo;s Quarterly Report on Form 10-Q, for the quarterly period ended June&nbsp;30, 2009, originally filed with the SEC on August&nbsp;13, 2009, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10#</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">License Agreement by and between Sankyo Co., Ltd. and Cyclacel Limited, dated September&nbsp;10, 2003, and letter amendments dated April&nbsp;1, 2004 and April&nbsp;28, 2004 (previously filed as Exhibit 10.1 to the Registrant&rsquo;s Quarterly Report on Form 10-Q, for the quarterly period ended June&nbsp;30, 2011, originally filed with the SEC on August&nbsp;12, 2011, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11#</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No. 4 to License Agreement between Daiichi Sankyo Company, Limited and Cyclacel Limited, dated July&nbsp;11, 2011 (previously filed as Exhibit 10.2 to the Registrant&rsquo;s Quarterly Report on Form 10-Q, for the quarterly period ended June&nbsp;30, 2011, originally filed with the SEC on August&nbsp;12, 2011, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock Purchase Agreement, dated November&nbsp;14, 2013, by and between Cyclacel Pharmaceuticals, Inc. and Aspire Capital Fund, LLC (previously filed as Exhibit 10.1 to the Registrant&rsquo;s Quarterly Report on Form 10-Q, originally filed with the SEC on November&nbsp;14, 2013, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Securities Purchase Agreement, by and between Cyclacel Pharmaceuticals, Inc. and certain investors (previously filed as Exhibit 10.1 to the Registrant&rsquo;s Current Report on Form 8-K, originally filed with the SEC on March&nbsp;4, 2015, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14&dagger;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Extension Agreement by and between Cyclacel Pharmaceuticals, Inc. and Spiro Rombotis, dated as of December&nbsp;22, 2016 (previously filed as Exhibit 10.14 to the Registrant&rsquo;s Annual Report on Form 10-K, originally filed with the SEC on March&nbsp;31, 2017, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15&dagger;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Extension Agreement by and between Cyclacel Pharmaceuticals, Inc. and Paul McBarron, dated as of December&nbsp;22, 2016 (previously filed as Exhibit 10.15 to the Registrant&rsquo;s Annual Report on Form 10-K, originally filed with the SEC on March&nbsp;31, 2017, and incorporated herein by reference).</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 11%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Exhibit</B></FONT><B><FONT STYLE="font-size: 8pt"><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif">Number</FONT></FONT></B></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="width: 88%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries of Cyclacel Pharmaceuticals, Inc. (previously filed as Exhibit 21 to the Registrant&rsquo;s Annual Report on Form 10-K, originally filed with the SEC on March&nbsp;26, 2014, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1**</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Independent Registered Public Accounting Firm.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in Exhibit 5.1).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1**</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power of Attorney.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&dagger;Indicates management compensatory plan, contract or
arrangement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">#Confidential treatment has been granted with respect to certain
portions of this exhibit, which portions have been omitted and filed separately with the Securities and Exchange Commission as
part of an application for confidential treatment pursuant to the Securities and Exchange Act of 1934, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">*Filed herewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">**Previously filed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 17.&nbsp;&nbsp;&nbsp;Undertakings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Insofar as indemnification for liabilities
arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to
the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission,
such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event
that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid
by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is
asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will,
unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction
the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed
by the final adjudication of such issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">The undersigned registrant hereby undertakes
that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 38pt"></TD><TD STYLE="width: 18pt">1)</TD><TD>For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed
as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant
pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement
as of the time it was declared effective; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 38pt"></TD><TD STYLE="width: 18pt">2)</TD><TD>For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of
prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such
securities at that time shall be deemed to be the initial bona fide offering thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Pursuant to the requirements of the Securities
Act of 1933, as amended, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned,
thereunto duly authorized in the City of Berkeley Heights, State of New Jersey, on July 6 , 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CYCLACEL PHARMACEUTICALS, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Paul McBarron</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul McBarron</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Operating Officer, Chief Financial Officer,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and Executive Vice President, Finance</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Pursuant to the requirements of the Securities
Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and as of the dates
indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Signature</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Title</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Date</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: Black 1pt solid">/s/ Spiro Rombotis</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Spiro Rombotis</P></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President &amp; Chief Executive Officer&nbsp;</FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)&nbsp;</FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 6</FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">,
    2017</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: Black 1pt solid">/s/ Paul McBarron</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Paul McBarron</P></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Operating Officer, Chief Financial Officer, and Executive Vice President, Finance (Principal Financial and Accounting Officer) and Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 6</FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">,
    2017</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: Black 1pt solid">*</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. David U&rsquo;Prichard</P></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman</FONT></TD>
    <TD>&nbsp;</TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 6</FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">,
    2017</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: Black 1pt solid">*</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Christopher Henney</P></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice Chairman</FONT></TD>
    <TD>&nbsp;</TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 6</FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">,
    2017</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: Black 1pt solid">*</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sir John Banham</P></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 6</FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">,
    2017</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: Black 1pt solid">*</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gregory Hradsky</P></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 6</FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">,
    2017</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: Black 1pt solid">*</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Lloyd Sems</P></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 6</FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">,
    2017</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">* By: </FONT></TD>
    <TD STYLE="width: 30%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Paul McBarron</FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 45%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 18%; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul McBarron</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attorney-in-fact</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>t1702049_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 70%; font-size: 10pt">&nbsp;</td>
    <td style="width: 30%; text-align: right; font-size: 10pt; text-decoration: underline"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><u>EXHIBIT 5.1</u></b></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: right">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: left; font-size: 10pt"><IMG SRC="t1702049_ex5-1logo.jpg" ALT=""></td>
    <td>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">666 Third Avenue</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">New York, New York 10017</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">212-935-3000</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">212-983-3115 fax</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">www.mintz.com</P></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">July 6, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cyclacel Pharmaceuticals, Inc.<BR>
200 Connell Drive, Suite 1500<BR>
Berkeley Heights, NJ 07922</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37.05pt">This opinion is furnished to you in connection
with the sale and issuance by Cyclacel Pharmaceuticals, Inc., a Delaware corporation (the &ldquo;Company&rdquo;), in a public offering
pursuant to the Registration Statement on Form S-1 (Registration Statement No. 333-218305), initially filed with the Securities
and Exchange Commission (the &ldquo;Commission&rdquo;) under the Securities Act of 1933, as amended (the &ldquo;Act&rdquo;), on
May 26, 2017, as amended (the &ldquo;Registration Statement&rdquo;), <FONT STYLE="background-color: white">of up to (i) $8,250,000
in&nbsp;Class&nbsp;A Units (the &ldquo;Class&nbsp;A Units&rdquo;), with each Class&nbsp;A Unit consisting of one share of the Company&rsquo;s
common stock, par value $0.001 per share (&ldquo;Common Stock&rdquo;), and a warrant to purchase one-half of one share of Common
Stock, (ii) $9,000,000 in&nbsp;Class&nbsp;B Units (the &ldquo;Class&nbsp;B Units&rdquo;, and collectively with the Class&nbsp;A
Units, the &ldquo;Units&rdquo;), with each Class&nbsp;B Unit consisting of one share of the Company&rsquo;s Series A convertible
preferred stock, par value $0.001 per share (&ldquo;Series A Preferred Stock&rdquo;) and a warrant to purchase one-half of one
share of Common Stock, (iii)&nbsp;shares of Common Stock issuable upon conversion of the shares of Series A Preferred Stock and
(iv)&nbsp;shares of Common Stock issuable upon exercise of the warrants (the &ldquo;Warrant Shares&rdquo;) issued under each of
the Class&nbsp;A Units and the Class&nbsp;B Units (each a &ldquo;Warrant&rdquo; and collectively, the &ldquo;Warrants&rdquo;) ((i)
through (iv)&nbsp;collectively, the &ldquo;Securities&rdquo;). The Units are to be sold by the Company pursuant to an underwriting
agreement (the &ldquo;Underwriting Agreement&rdquo;) to be entered into by and between the Company and Ladenburg Thalmann&nbsp;&amp;
Co., Inc. on behalf of themselves and as representative to the several underwriters to be named therein. The Securities are to
be offered and sold in the manner described in the Registration Statement and the related prospectus included therein (the &ldquo;Prospectus&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37.05pt">In connection with this opinion, we have
examined originals or copies, certified or otherwise identified to our satisfaction, of: (i)&nbsp;the Amended and Restated Certificate
of Incorporation of the Company, as amended through the date hereof; (ii)&nbsp;the Amended and Restated Bylaws of the Company,
as amended through the date hereof; (iii)&nbsp;the Certificate of Designation of Preferences, Rights and Limitations of Series
A Convertible Preferred Stock to be filed with the Secretary of State of the State of Delaware, (iv)&nbsp;certain resolutions of
the Board of Directors of the Company (the &ldquo;Board&rdquo;) relating to the issuance, sale and registration of the Securities;
(v)&nbsp;the Registration Statement; (vi)&nbsp;the Prospectus and (vii)&nbsp;the Underwriting Agreement. In addition, we have examined
originals or copies, certified or otherwise identified to our satisfaction, of certain other corporate records, documents, instruments
and certificates of public officials and of the Company, and we have made such inquiries of officers of the Company and public
officials and considered such questions of law as we have deemed necessary for purposes of rendering the opinions set forth herein.
Our opinions are limited to the matters stated herein and no opinion is implied or may be inferred beyond the matters expressly
stated. As to certain factual</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Mintz, Levin, Cohn, Ferris, Glovsky and
Popeo, P.C.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps">Boston
| Washington | New York | Stamford | Los Angeles | San Francisco | San Diego | London </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps">Mintz, Levin, Cohn, Ferris,
Glovsky and Popeo, P.C.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">July 6, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Page </FONT>2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">matters, we have relied upon a certificate of an officer of
the Company and have not sought to independently verify such matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37.05pt">In rendering our opinion set forth below,
we have assumed that (i)&nbsp;each document submitted to us is accurate and complete; (ii)&nbsp;each such document that is an original
is authentic; (iii)&nbsp;each such document that is a copy conforms to an authentic original; and (iv)&nbsp;all signatures (other
than signatures on behalf of the Company) on each such document are genuine.&nbsp;We have further assumed the legal capacity of
natural persons, and we have assumed that each party to the documents we have examined or relied on (other than the Company) has
the legal capacity or authority and has satisfied all legal requirements that are applicable to that party to the extent necessary
to make such documents enforceable against that party.&nbsp;We have further assumed that the Company will not in the future issue
or otherwise make unavailable so many shares of Common Stock that there are insufficient remaining authorized but unissued shares
of Common Stock for issuance pursuant to exercise of the Warrants.&nbsp;We have also assumed that all of the shares of Common Stock
issuable or eligible for issuance pursuant to exercise of the Warrants following the date hereof will be issued for not less than
par value.&nbsp;We have not verified any of those assumptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37.05pt">Based upon, subject to and limited by
the foregoing, we are of the opinion that (i)&nbsp;the shares of Common Stock included in the Class&nbsp;A Units, when issued against
payment therefor as set forth in the Registration Statement, will be validly issued, fully paid and&nbsp;non-assessable;&nbsp;(ii)&nbsp;the
shares of Series A Preferred Stock included in the Class&nbsp;B Units, when issued against payment therefor as set forth in the
Registration Statement, will be validly issued, fully paid and&nbsp;non-assessable;&nbsp;(iii)&nbsp;the shares of Common Stock,
when issued upon conversion of the shares of Series A Preferred Stock, will be validly issued, fully paid and&nbsp;non-assessable&nbsp;(iv)&nbsp;the
Warrants, when issued as set forth in the Registration Statement will be legal, valid and binding obligations of the Company, enforceable
against the Company in accordance with their terms; (v)&nbsp;the Warrant Shares, when issued upon exercise of the Warrants against
payment therefor as set forth in the Registration Statement, will be validly issued, fully paid and&nbsp;non-assessable; (vi) the
Class A Units, when duly delivered by the Company against the payment of consideration therefor and as contemplated in the Registration
Statement, will constitute valid and legally binding obligations of the Company; and (vii) the Class B Units, when duly delivered
by the Company against the payment of consideration therefor and as contemplated in the Registration Statement, will constitute
valid and legally binding obligations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37.05pt">We express no opinion as to matters governed
by any laws other than the Delaware General Corporation Law and the federal laws of the United States of America, as in effect
on the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37.05pt">We hereby consent to the filing of this
opinion as an exhibit to the Registration Statement and to the reference to our firm under the caption &ldquo;Legal Matters&rdquo;
in the Prospectus. In giving such permission, we do not admit hereby that we come within the category of persons whose consent
is required under Section&nbsp;7 of the Act, or the rules and regulations of the Commission thereunder. This opinion is expressed
as of the date hereof, and we disclaim any undertaking to advise you of any subsequent changes in the facts stated or assumed herein
or of any subsequent changes in applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Very truly yours,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">/s/ Mintz, Levin, Cohn, Ferris, Glovsky &amp; Popeo, P.C.</FONT></TD>
    <TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mintz, Levin, Cohn, Ferris, Glovsky &amp;
Popeo, P.C.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Mintz, Levin, Cohn, Ferris, Glovsky and
Popeo, P.C.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps">Boston
| Washington | New York | Stamford | Los Angeles | San Francisco | San Diego | London </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>t1702049_ex5-1logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 t1702049_ex5-1logo.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ (0#5 P$1  (1 0,1 ?_$ )    (#  ,!
M      D*  <(! 4&"P$!                     !    8" 0$$ P@*"Q$
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M-&()_@'8&F)#*-O\MV_-9\@U(<:L4U.U-O/86VHSB>S(RJ=E+;4QC7BN<+
M-G%SJY)KLQ&M* +/@QP+2D=]8H)]6++!DUP0A/!CPOOX #Q<@R9W ^)DL.0@
MR/LQW\@"(0Q!!D7V,9SG.,?;Z!$+SQGU8\=7R\V2^;]-= \-5_U9UW\A8C\
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;^-=77ZN)G\').@-OT R_^E?_ +[/_8CT'__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
